Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) just unveiled an update.
ResMed Inc., whose NYSE-listed common stock is traded on the ASX via a 10:1 CHESS Depositary Interest structure under the code RMD, reported updated figures for its CDI and underlying securities on issue for December 2025. The total number of CDIs on issue over quoted securities increased slightly to 579,449,490, a net rise of 62,160 over the month, mainly due to net transfers between CDIs and common stock listed on the NYSE. The company also reported movements in its non-CDI securities, with a net decrease reflecting transfers between ASX CDIs and NYSE common stock, issuance of new shares related to employee stock options, restricted stock units and purchase plans, and ongoing share repurchases on the NYSE, indicating active capital management and routine adjustments to its cross-listed share structure.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a medical technology company focused on developing and manufacturing devices and software solutions for sleep apnea, respiratory care and related chronic conditions, with its shares primarily traded on the NYSE and represented on the ASX through CHESS Depositary Interests (CDIs) on a 10:1 basis.
Average Trading Volume: 1,176,152
Technical Sentiment Signal: Buy
Current Market Cap: A$53.49B
For a thorough assessment of RMD stock, go to TipRanks’ Stock Analysis page.